combination therapy with glp-1 receptor agonist and sglt2 inhibitor Blood pressure effects of inhibitors GLP‐1 agonists: Mechanisms, trial evidence and Real‐world data - Belančić - British Journal of Clinical Pharmacology Perspectives in weight control in
Description
& Loukianova, L
Researchers who escalated too quickly bore the brunt of gastrointestinal side effects, while those who followed the standard four-week titration intervals reported significantly better tolerability
Safety considerations are critical in determining treatment duration
doi: 10.1016/j.metabol.2019.154045
Eur J Cell Biol (2017) 96:24053
In clinical trials targeting obese populations, Survodutide demonstrated varying degrees of weight loss across dosages ranging from 0.6 to 4.8 milligrams
